Academic literature on the topic 'Antagonists'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Antagonists.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Antagonists"
Otto-Hanson, L. K., Z. Grabau, C. Rosen, C. E. Salomon, and L. L. Kinkel. "Pathogen Variation and Urea Influence Selection and Success of Streptomyces Mixtures in Biological Control." Phytopathology® 103, no. 1 (January 2013): 34–42. http://dx.doi.org/10.1094/phyto-06-12-0129-r.
Full textDilger, James P., Ana Maria Vidal, Man Liu, Claire Mettewie, Takahiro Suzuki, Anh Pham, and Deeptankar Demazumder. "Roles of Amino Acids and Subunits in Determining the Inhibition of Nicotinic Acetylcholine Receptors by Competitive Antagonists." Anesthesiology 106, no. 6 (June 1, 2007): 1186–95. http://dx.doi.org/10.1097/01.anes.0000267602.94516.7f.
Full textPresti, M. E., and J. D. Gardner. "Receptor antagonists for gastrointestinal peptides." American Journal of Physiology-Gastrointestinal and Liver Physiology 264, no. 3 (March 1, 1993): G399—G406. http://dx.doi.org/10.1152/ajpgi.1993.264.3.g399.
Full textRobben, J. H., M. Sze, N. V. A. M. Knoers, and P. M. T. Deen. "Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus." American Journal of Physiology-Renal Physiology 292, no. 1 (January 2007): F253—F260. http://dx.doi.org/10.1152/ajprenal.00247.2006.
Full textOkada, H., H. Suzuki, Y. Kanno, Y. Yamamura, and T. Saruta. "Chronic and selective vasopressin blockade in spontaneously hypertensive rats." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 267, no. 6 (December 1, 1994): R1467—R1471. http://dx.doi.org/10.1152/ajpregu.1994.267.6.r1467.
Full textBarth, Francis, and Murielle Rinaldi-Carmona. "The Development of Cannabinoid Antagonists." Current Medicinal Chemistry 6, no. 8 (August 1999): 745–55. http://dx.doi.org/10.2174/0929867306666220401143808.
Full textSchulz, Ashley N., Rima D. Lucardi, and Travis D. Marsico. "Successful Invasions and Failed Biocontrol: The Role of Antagonistic Species Interactions." BioScience 69, no. 9 (August 7, 2019): 711–24. http://dx.doi.org/10.1093/biosci/biz075.
Full textBödder, Johanna, Leanne M. Kok, Jonathan A. Fauerbach, Georgina Flórez-Grau, and I. Jolanda M. de Vries. "Tailored PGE2 Immunomodulation of moDCs by Nano-Encapsulated EP2/EP4 Antagonists." International Journal of Molecular Sciences 24, no. 2 (January 11, 2023): 1392. http://dx.doi.org/10.3390/ijms24021392.
Full textGeling, Olga, and Hans-Georg Eichler. "Should 5-Hydroxytryptamine-3 Receptor Antagonists Be Administered Beyond 24 Hours After Chemotherapy to Prevent Delayed Emesis? Systematic Re-Evaluation of Clinical Evidence and Drug Cost Implications." Journal of Clinical Oncology 23, no. 6 (February 20, 2005): 1289–94. http://dx.doi.org/10.1200/jco.2005.04.022.
Full textVarma, Daya R. "Ligand-independent negative chronotropic responses of rat and mouse right atria to β-adrenoceptor antagonists." Canadian Journal of Physiology and Pharmacology 77, no. 12 (November 15, 1999): 943–49. http://dx.doi.org/10.1139/y99-099.
Full textDissertations / Theses on the topic "Antagonists"
Horn, Johanna. "Calcium antagonists in stroke." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2001. http://dare.uva.nl/document/58263.
Full textPaoletta, Silvia. "Designing adenosine receptors antagonists using an in silico approach." Doctoral thesis, Università degli studi di Padova, 2012. http://hdl.handle.net/11577/3422906.
Full textL’adenosina è un neuromodulatore che regola molti processi fisiopatologici attraverso l’attivazione di quattro diversi recettori accoppiati a proteine G (GPCRs), classificati come sottotipi A1, A2A, A2B e A3. I recettori adenosinici sono ubiquitari nell’organismo umano e la loro attivazione è responsabile di numerosi effetti in diversi organi. Proprio per questo motivo la regolazione dell’attività di questi recettori può avere interessanti applicazioni terapeutiche. Il principale obiettivo di questo progetto è stato l’analisi in silico a livello molecolare dei recettori adenosinici, ed in particolare dei recettori adenosinici umani A2A e A3, per guidare la scoperta e l’ottimizzazione strutturale di nuovi antagonisti adenosinici potenti e selettivi. Le strutture cristallografiche del recettore adenosinico umano A2A, recentemente pubblicate, forniscono dettagliate informazioni strutturali utili per supportare studi di homology modeling e approcci di drug design di tipo structure-based. In particolare, la struttura cristallografica del recettore adenosinico umano A2A, in complesso con l’antagonista potente e selettivo ZM241385, è stata utilizzata come templato per la costruzione di un modello per omologia del recettore adenosinico umano A3. Inoltre, con l’intento di selezionare il protocollo di docking molecolare più adatto per la famiglia dei recettori adenosinici, la struttura cristallografica del recettore adenosinico A2A è stata utilizzata per effettuare simulazioni di docking con diversi softwares in parallelo. Successivamente, le conformazioni ottenute dal docking sono state confrontate con la pose cristallografica di ZM241385 per selezionare il protocollo di docking che fosse in grado di riprodurre al meglio questo sistema molecolare e che potesse quindi essere usato per i successivi studi di docking. Sono stati quindi effettuati studi di docking molecolare di vari antagonisti adenosinici sul modello del recettore A3 e sulla struttura cristallografica del recettore A2A, in modo da ricavare informazioni che potessero facilitare il processo di ottimizzazione dei composti. Sono stati infatti analizzati numerosi nuovi composti appartenenti a classi note di antagonisti adenosinici, tra cui composti triazolotriazinici e tirazolotriazolopirimidinici, in modo da suggerire modifiche strutturali in grado di modularne l’affinità nei confronti dei vari sottotipi recettoriali adenosinici, di aumentarne la solubilità o di superarne i punti di instabilità metabolica. Diversi derivati con strutture semplificate, come per esempio composti pirazolopirimidinonici, ftalazinonici e triazolotriazinici, sono stati inoltre proposti come nuovi composti con attività antagonista nei confronti dei recettori adenosinici. Le informazioni ricavate grazie agli studi di docking hanno permesso l’identificazione di caratteristiche strutturali degli antagonisti adenosinici fondamentali per l’interazione con questi recettori. Queste informazioni sono state quindi applicate alla progettazione di derivati fluorescenti per il recettore adenosinico A3, che risultano particolarmente interessanti per il loro potenziale utilizzo in saggi farmacologici. In conclusione, quindi, questo studio sui recettori adenosinici dimostra come l’integrazione di metodologie computazionali con il lavoro sintetico e farmacologico risulta essere una strategia efficace per lo sviluppo di nuovi ligandi dei recettori adenosinici, a potenziale interesse terapeutico, e per il chiarimento di importanti aspetti strutturali riguardanti questa famiglia recettoriale e più in generale tutti i GPCRs.
Lee, Hyosung. "DEVELOPMENT OF NOVEL AHR ANTAGONISTS." UKnowledge, 2010. http://uknowledge.uky.edu/gradschool_diss/103.
Full textPasanisi, F. "Clinical pharmacology of calcium antagonists." Thesis, University of Glasgow, 1986. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.381477.
Full textMcClean, Mercedes. "NMDA antagonists as antinociceptive agents." Thesis, University of Bristol, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.311427.
Full textAbusara, Osama. "Neuropeptide antagonists for cancer treatment." Thesis, University of Manchester, 2017. https://www.research.manchester.ac.uk/portal/en/theses/neuropeptide-antagonists-for-cancer-treatment(e2f22b9f-f0a7-432d-89c4-7e65a2c71b69).html.
Full textYocum, David. "Effective use of TNF antagonists." BioMed Central, 2004. http://hdl.handle.net/10150/610348.
Full textHughes, G. A. "Novel, potent antagonists of capsaicin." Thesis, University College London (University of London), 2005. http://discovery.ucl.ac.uk/1445556/.
Full textSozynski, Jan Maria. "Synthesis of Novel Ethylene Antagonists." Thesis, Curtin University, 2022. http://hdl.handle.net/20.500.11937/89600.
Full textArthuso, Fernanda dos Santos. "Adaptação de células CHO secretoras de prolactina humana e seus antagonistas para o crescimento em suspensão." Universidade de São Paulo, 2011. http://www.teses.usp.br/teses/disponiveis/85/85131/tde-20062011-110202/.
Full textThe Hormone Group of the Biotechnology Center of IPEN has developed different cells lines of genetically modified chinese hamster ovary cells (CHO) for the expression of heterologus protein like human prolactin (hPRL) and its analogs/antagonists (S179D-hPRL and G129R-hPRL). All cell lines for expression are however cultured in monolayer culture dish and depend on fetal bovine serum (FBS) in the medium for an efficient growth. Cells in suspension show a great industrial-pharmaceutical interest, especially for the cultivation facility and scale enlargement as well as for volumetric productivity. We developed a protocol for adapting CHO cells to suspension growth, in spinner flasks. The adaption of our cell lines producing hPRL; S179D-hPRL and G129R-hPRL to suspension growth and in serum-free medium was obtained. We also carried out laboratory scale production with the three suspension-adapted culture line cells and the corresponding purification and characterization of four heterologous proteins, including glycosylated human prolactin (G-hPRL).
Books on the topic "Antagonists"
Godfraind, T., R. Paoletti, S. Govoni, and P. M. Vanhoutte, eds. Calcium Antagonists. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1725-8.
Full textLydtin, Helmut, and Peter Trenkwalder. Calcium Antagonists. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74887-5.
Full textRenko, Hal. The antagonists. Wokingham, England: Addison-Wesley, 1985.
Find full textRenko, Hal. The antagonists. Wokingham, Berkshire: Addison-Wesley, 1985.
Find full textRenko, Hal. The antagonists. Wokingham, England: Addison-Wesley, 1985.
Find full textNayler, W. G. Calcium antagonists. London: Academic, 1988.
Find full textRenko, Hal. The antagonists. Wokingham, Berkshire: Addison-Wesley, 1985.
Find full textRenko, Hal. The antagonists. Wokingham, Berkshire: Addison-Wesley, 1985.
Find full textGermany), MARTa Herford (Herford, ed. OWL4: Gegenspieler = antagonists. Dortmund: Verlag Kettler, 2016.
Find full textUvnäs, Börje, ed. Histamine and Histamine Antagonists. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-75840-9.
Full textBook chapters on the topic "Antagonists"
Landau, Neil. "Antagonists." In The TV Showrunner's Roadmap, 194–210. 2nd ed. New York: Routledge, 2022. http://dx.doi.org/10.4324/9781003041115-9.
Full textKrizanova, Olga, Philippe Lory, and Arnold Schwartz. "Structure-Function Studies of the Voltage-Dependent Calcium Channels." In Calcium Antagonists, 1–8. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1725-8_1.
Full textGaviraghi, G., and T. Godfraind. "New Insight into the Vascular Properties of Lacidipine." In Calcium Antagonists, 65–69. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1725-8_10.
Full textLittle, W. C., and C. P. Cheng. "Effect of Felodipine on Left Ventricular Performance in Conscious Dogs: Assessment by Left Ventricular Pressure-Volume Analysis." In Calcium Antagonists, 71–76. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1725-8_11.
Full textMancia, Giuseppe. "Lacidipine in the Treatment of Hypertension: Clinical Data." In Calcium Antagonists, 77–85. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1725-8_12.
Full textVerdonck, F., F. V. Bielen, L. Ver Donck, and M. Borgers. "Insights in the Cardioprotective Mechanism of the New Drug R56865." In Calcium Antagonists, 87–92. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1725-8_13.
Full textMorgan, T., and A. Anderson. "Do the Differences Between Calcium Antagonists Matter When Treating Hypertension?" In Calcium Antagonists, 93–98. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1725-8_14.
Full textBoraso, A., A. Cargnoni, A. Maggi, R. Ferrari, and O. Visioli. "Effects of Lacidipine on Ischemic and Reperfused Myocardium." In Calcium Antagonists, 99–106. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1725-8_15.
Full textTulenko, Thomas N., R. Preston Mason, Meng Chen, Hiromi Tasaki, Daniel Rock, and David Stepp. "Atherogenic Activity caused by Excess Membrane Cholesterol in Arterial Smooth Muscle: Role of Calcium Channels." In Calcium Antagonists, 107–15. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1725-8_16.
Full textNayler, Winifred G. "Understanding the Initiating Factors in Atherosclerosis: Implications for Intervention." In Calcium Antagonists, 117–24. Dordrecht: Springer Netherlands, 1993. http://dx.doi.org/10.1007/978-94-011-1725-8_17.
Full textConference papers on the topic "Antagonists"
Maslak, Diana, A. Orunova, Irina Feklistova, Irina Grineva, Tatyana Skakun, and V. Lomonosova. "Search for isolates of endophytic bacteria-antagonists of phytopathogens." In Scientific International Symposium "Plant Protection – Achievements and Perspectives". Institute of Genetics, Physiology and Plant Protection, Republic of Moldova, 2023. http://dx.doi.org/10.53040/ppap2023.69.
Full textVoitka, D. V., E. K. Yuzefovich, and A. V. Mikhnyuk. "Features of relationship of Trichoderma saprotrophic fungi-antagonists with the phytopathogenic micromycetes." In 2nd International Scientific Conference "Plants and Microbes: the Future of Biotechnology". PLAMIC2020 Organizing committee, 2020. http://dx.doi.org/10.28983/plamic2020.275.
Full textBevan, Jane, and S. Heptinstall. "BOW CAN WE INHIBIT 5HT-INDUCED PLATELET AGGREGATION AND WHY SHOULD WE BOTHER?" In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643853.
Full textRibeiro, Fernanda Cristina Poscai, and Everton Lopes Rodrigues. "Integrative review of the use of NMDA antagonists for TBI treatment." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.190.
Full textVasilchenko, N. G., A. V. Gorovtsov, V. A. Chistyakov, and M. S. Mazanko. "BACTERIA OF THE ORDER BACILLALES AS PROMISING ANTAGONISTS OF FUSARIUM PATHOGENS AND THEIR IMPACT ON WINTER WHEAT PLANTS." In INNOVATIVE TECHNOLOGIES IN SCIENCE AND EDUCATION. DSTU-Print, 2020. http://dx.doi.org/10.23947/itno.2020.324-327.
Full text"IMAGES OF ANTAGONISTS IN THE RELIGIOUS AND MYTHOLOGICAL REPRESENTATIONS OF THE YAKUTS." In Культура, наука, образование: проблемы и перспективы. Нижневартовский государственный университет, 2021. http://dx.doi.org/10.36906/ksp-2021/36.
Full textUdit, Andrew K. "Engineered virus-like nanoparticle heparin antagonists." In 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). IEEE, 2013. http://dx.doi.org/10.1109/embc.2013.6610451.
Full textSantos, Nathalia Lima Schramm dos, William Wallace dos Santos Silva, Geovanna da Silva Campos Conceição, Gabriel Serra Almeida, Jacqueline Oliveira Freitas, Breno Silva Reis, and Lucas Santos Silva. "CGRP antagonists: Perspectives on migraine prophylaxis." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.193.
Full textREBER, ANNIE, MARIE-HELENE LEROY, and BERNARD POITEVIN. "VISUO-VESTIBULAR REFLEXES ADJUSTMENT BY GABA ANTAGONISTS." In Proceedings of the International School of Biophysics. WORLD SCIENTIFIC, 1998. http://dx.doi.org/10.1142/9789812816887_0028.
Full textFeklistova, Iryna, Diana Maslak, N. Akiev, T. Skakun, Irina Grineva, and V. Lomonosova. "Search for micromycetes – antagonists of phytopathogenic microorganisms." In Scientific International Symposium "Plant Protection – Achievements and Perspectives". Institute of Genetics, Physiology and Plant Protection, Republic of Moldova, 2023. http://dx.doi.org/10.53040/ppap2023.64.
Full textReports on the topic "Antagonists"
Wilson, Charles, and Edo Chalutz. Biological Control of Postharvest Diseases of Citrus and Deciduous Fruit. United States Department of Agriculture, September 1991. http://dx.doi.org/10.32747/1991.7603518.bard.
Full textBoisclair, Yves R., and Arieh Gertler. Development and Use of Leptin Receptor Antagonists to Increase Appetite and Adaptive Metabolism in Ruminants. United States Department of Agriculture, January 2012. http://dx.doi.org/10.32747/2012.7697120.bard.
Full textAltstein, Miriam, and Ronald J. Nachman. Rational Design of Insect Control Agent Prototypes Based on Pyrokinin/PBAN Neuropeptide Antagonists. United States Department of Agriculture, August 2013. http://dx.doi.org/10.32747/2013.7593398.bard.
Full textAltstein, Miriam, and Ronald Nachman. Rationally designed insect neuropeptide agonists and antagonists: application for the characterization of the pyrokinin/Pban mechanisms of action in insects. United States Department of Agriculture, October 2006. http://dx.doi.org/10.32747/2006.7587235.bard.
Full textTracy, Michael. Improved Muscarinic Antagonists as Anticholinesterase Antidotes. Fort Belvoir, VA: Defense Technical Information Center, March 1991. http://dx.doi.org/10.21236/ada242697.
Full textSchmidt, Jakob. Mass-Screening of Curarimimetic Neurotoxin Antagonists. Fort Belvoir, VA: Defense Technical Information Center, March 1990. http://dx.doi.org/10.21236/ada222729.
Full textTracy, Michael. Improved Muscarinic Antagonists as Anticholinesterase Antidotes. Fort Belvoir, VA: Defense Technical Information Center, February 1990. http://dx.doi.org/10.21236/ada223689.
Full textKao, C. Y. Site-Specific Antagonists to Tetrodotoxin and Saxitoxin. Fort Belvoir, VA: Defense Technical Information Center, May 1988. http://dx.doi.org/10.21236/adb124671.
Full textKao, C. Y. Site-Specific Antagonists to Tetrodotoxin and Saxitoxin. Fort Belvoir, VA: Defense Technical Information Center, May 1990. http://dx.doi.org/10.21236/adb145447.
Full textChalutz, Edo, Michael Wisniewski, Samir Droby, Yael Eilam, and Ilan Chet. Mode of Action of Yeast Biocontrol Agents of Postharvest Diseases of Fruits. United States Department of Agriculture, June 1996. http://dx.doi.org/10.32747/1996.7613025.bard.
Full text